|Bid||18.91 x 200|
|Ask||19.93 x 2000|
|Day's Range||18.68 - 19.38|
|52 Week Range||11.11 - 22.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.75|
Study to evaluate Oral KORSUVA (CR845/difelikefalin) for the Treatment of Pruritus in Stage III-V Chronic Kidney Disease (CKD) Patients BOONTON, N.J , July 19, 2018 /PRNewswire/ -- Enteris BioPharma, ...
Cara Therapeutics, Inc. (CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $19.00 per share. The offering is expected to close on or about July 23, 2018, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Cara Therapeutics, are expected to be approximately $85.5 million. In addition, Cara Therapeutics granted the underwriters a 30-day option to purchase up to 675,000 additional shares of its common stock on the same terms and conditions.
On a day stocks rose on optimism over earnings and the economy, United Continental reported strong profit growth and Cara Therapeutics announced a secondary offering.
NEW YORK, NY / ACCESSWIRE / July 18, 2018 / U.S. stocks closed up on Tuesday, as the Federal Reserve announced that it would be flexible in the face of changing conditions and will not move too quickly ...
Cara Therapeutics, Inc. (CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors, today announced that it has commenced an underwritten public offering of 4,500,000 shares of its common stock. In addition, Cara Therapeutics expects to grant certain of the underwriters a 30-day option to purchase up to 675,000 additional shares of its common stock on the same terms and conditions. All of the shares in the proposed offering are to be sold by Cara Therapeutics.
STAMFORD, Conn., July 11, 2018-- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively ...
Jim Cramer rattles off his take on callers' favorite stocks, including a drugmaker that's topping its competition.
Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.
Cara Therapeutics Inc (NASDAQ: CARA ) stock spiked 34 percent Wednesday after the company reported that a Phase 2/3 trial for intravenous CR845 met primary and secondary endpoints. The investor bullishness ...
On June 27, Cara Therapeutics (CARA) announced positive top-line results from its phase two/three trial evaluating the efficacy of its investigational post-surgical analgesic therapy, the Korsuva injection (or I.V. CR845), in reducing pain intensity and post-operative nausea and vomiting after abdominal surgeries. This announcement drove Cara Therapeutics stock up by around 9.8% to reach $18.0 on June 27. Of the eight analysts that are covering Cara Therapeutics in June 2018, three recommend a “strong buy,” and five recommend a “buy.” Cara Therapeutics also aims to expand Korsuva’s label in other indications.
NEW YORK, NY / ACCESSWIRE / June 28, 2018 / U.S. equities fell sharply on Wednesday, weighed by losses from the consumer staples and technology sectors. The Dow Jones Industrial Average decreased 0.68 ...
On a day stocks moved lower, Conagra Brands and Pinnacle Foods announced a merger and Cara Therapeutics reported a clinical trial success.
Stocks that moved substantially or traded heavily Wednesday: Concho Resources Inc., up $6.09 to $137.78 Energy sector stocks climbed with the price of oil amid signs of supply pressure. Conagra Brands ...
The Stamford, Conn.-based drug maker saw its shares soar as the company announced positive data in a Phase 2/3 trial of a treatment for pain in patients who are currently undergoing abdominal surgery. The treatment also proved to be a success in reducing nausea and vomiting after surgery. CARA stock was up about 11.6% on Wednesday following the news, sending the stock to a price of about $18.34 per share by mid-afternoon.
Cara Therapeutics Inc (NASDAQ: CARA ) popped more than 32 percent Wednesday morning after management reported positive top-line data for a drug candidate. What Happened A Phase 2/3 trial of intravenous ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Medigus Ltd (NASDAQ: MDGS ) stock was trading higher ...
CR845 achieved statistical significance for the study’ s primary endpoint of pain relief over the 0 to 24- hour period post-surgery for combined surgeries at the 1.0 mcg/kg dose-. CR845 treatment resulted ...
Heron Therapeutics, Cara Therapeutics and Alkermes are discovering novel replacements for dangerous opioidsAbout 2.1 million people in the U.S. suffer from opioid abuse. While investors are focused on trade wars as a potential threat to their wealth, drug abuse may be the bigger risk. Fortunately, three biotech companies are coming to the rescue, which makes them good investments.
Four stocks have been lined up for today's assessment, and they are: Calithera Biosciences Inc. (CALA), Cara Therapeutics Inc. (CARA), Celgene Corp. (CELG), and Celldex Therapeutics Inc. (CLDX). Shares in South San Francisco, California headquartered Calithera Biosciences Inc. jumped 5.53%, ending Wednesday's trading session at $5.25. The stock recorded a trading volume of 552,298 shares, which was higher than its three months average volume of 426,620 shares.